Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2016

View Archived Issues

Mutations in ZAS may be associated with congenital myopathy

Mersana's XMT-1536 targets tumors expressing sodium-dependent phosphate transport protein 2B

TRIP-13 identified as a therapeutic target in hepatocellular carcinoma

Vasohibin-1 shows promise as a therapeutic target for diabetic erectile dysfunction

Ionis and MD Anderson form strategic alliance to discover and develop novel cancer therapeutics

Darzalex receives European conditional marketing authorization for multiple myeloma

Positive topline results from a first-in-human trial of broad spectrum MVA-BN RSV vaccine

Catabasis' SREBP inhibitors show potential for NASH

Merck & Co. patent orexin receptor antagonists

ETHZ, Roche and Universität Zürich disclose CB2 receptor ligands

ECUST and SIMM report dipeptidyl peptidase IV inhibitors

Enanta Pharmaceuticals discloses farnesoid X receptor agonists

IOmet Pharma divulges indoleamine and tryptophan dioxygenase inhibitors

Bayer Schering Pharma announces t-PA inhibitors

New studies support utility of GastroPanel to predict stomach cancer risk

Advanced Accelerator Applications scales up Lutathera production

Survival benefit with Pentaglobin in severe infections caused by multidrug-resistant bacteria

Onoclys BioPharma announces licensing developments

FDA awards fast track designation for AEB-1102 in hyperargininemia

Boehringer Ingelheim and Biomed X establish a global research team

Avastin approved in Japan for cervical cancer

Phase III trial results presented for alirocumab in Japan

Alimera reports real world data on Iluvien in patients with DME

Exelixis reports phase II results for cabozantinib

Interim phase II data for bardoxolone methyl show improvement in renal function

Arbor Pharmaceuticals set to acquire XenoPort

ZVex/mIL12 shows promising antitumor effect in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.